ArticleJournal of perinatology : official journal of the California Perinatal Association2026
Anti-cytomegalovirus medications among very low birth weight infants in the United States from 2016 to 2023.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveVery low birth weight (VLBW) infants are at risk for congenital and postnatally acquired cytomegalovirus (CMV). NICU utilization rates for anti-CMV active medications are unknown. We assessed utilization of these medications among VLBW infants admitted to NICUs across the U.S. over an 8-year period.
methodsRepeated cross-sectional study using data from the Premier Healthcare Database, including inborn VLBW infants admitted to NICUs from 2016 to 2023. Daily pharmacy charge data were used to estimate the annual proportion of infants who received anti-CMV medications at least once.
resultsAmong 75,731 VLBW infants admitted to 498 NICUs, 309 (0.4%) infants from 115 NICUs received anti-CMV medications; 228 infants received valganciclovir, 212 infants received ganciclovir. The proportion of VLBW infants receiving these medications was less than 1% annually. Most administrations started after 4 weeks (n = 261,84.5%).
conclusionUsage of anti-CMV medications among VLBW infants in U.S. NICUs was low and usually administered after 4 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.